Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rebekah Caza"'
Autor:
Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay R. Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A. Bejan, Merrida Childress, Ingrid Anderson, Kyle Rawling, Rhea M. Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing V. Dudley, P. Brent Ferrell, Michael Byrne, Stephen A. Strickland, Gregory D. Ayers, Bennett A. Landman, Emily F. Mason, Ruben A. Mesa, Jeanne M. Palmer, Laura C. Michaelis, Michael R. Savona
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferati
Autor:
Michael R. Savona, Laura C. Michaelis, Jeanne M. Palmer, Ruben A. Mesa, Emily F. Mason, Bennett A. Landman, Gregory D. Ayers, Stephen A. Strickland, Michael Byrne, P. Brent Ferrell, Channing V. Dudley, Aunshka Collins, Laura Dugger, Rebekah Caza, Ashley Moncrief, Rhea M. Simons, Kyle Rawling, Ingrid Anderson, Merrida Childress, Cosmin A. Bejan, Yucheng Tang, Hyeonsoo Moon, Yuankai Huo, Run Fan, Sheau-Chiann Chen, Tess Stopczynski, Sanjay R. Mohan, Brandon McMahon, Matthew T. Villaume, Ashwin Kishtagari, Tamara K. Moyo
Supplemental Tables S1-S9 Supplemental Figures S1-S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00824c6ff87fc381e622ce00f6089201
https://doi.org/10.1158/1078-0432.22787600.v1
https://doi.org/10.1158/1078-0432.22787600.v1
Autor:
Michael R. Savona, Laura C. Michaelis, Jeanne M. Palmer, Ruben A. Mesa, Emily F. Mason, Bennett A. Landman, Gregory D. Ayers, Stephen A. Strickland, Michael Byrne, P. Brent Ferrell, Channing V. Dudley, Aunshka Collins, Laura Dugger, Rebekah Caza, Ashley Moncrief, Rhea M. Simons, Kyle Rawling, Ingrid Anderson, Merrida Childress, Cosmin A. Bejan, Yucheng Tang, Hyeonsoo Moon, Yuankai Huo, Run Fan, Sheau-Chiann Chen, Tess Stopczynski, Sanjay R. Mohan, Brandon McMahon, Matthew T. Villaume, Ashwin Kishtagari, Tamara K. Moyo
Purpose:Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66f4bf7c7d922639cc2f4c32c3e57a35
https://doi.org/10.1158/1078-0432.c.6637754.v1
https://doi.org/10.1158/1078-0432.c.6637754.v1